Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.78+0.08 (+2.16%)
Close on Nov 18, 2026Market cap $474.43MP/E –Yield –
Aquestive Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Aquestive Therapeutics's total assets was $132.10M at Jun 30, 2026. For fiscal 2025 it was $160.43M, up 58.2% from the year before. The highest annual figure on record is $160.43M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.43M | +58.2% |
| FY2024 | Dec 31, 2024 | $101.42M | +76.6% |
| FY2023 | Dec 31, 2023 | $57.42M | +0.6% |
| FY2022 | Dec 31, 2022 | $57.07M | -7.9% |
| FY2021 | Dec 31, 2021 | $61.99M | -1.4% |
| FY2020 | Dec 31, 2020 | $62.88M | -19.9% |
| FY2019 | Dec 31, 2019 | $78.48M | -9.6% |
| FY2018 | Dec 31, 2018 | $86.85M | +101.4% |
| FY2017 | Dec 31, 2017 | $43.12M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $132.10M | +41.0% |
| Q1 FY2026 | Mar 31, 2026 | $141.13M | +38.0% |
| Q4 FY2025 | Dec 31, 2025 | $160.43M | +58.2% |
| Q3 FY2025 | Sep 30, 2025 | $163.56M | +48.7% |
| Q2 FY2025 | Jun 30, 2025 | $93.70M | -20.3% |
| Q1 FY2025 | Mar 31, 2025 | $102.23M | -21.1% |
| Q4 FY2024 | Dec 31, 2024 | $101.42M | +76.6% |
| Q3 FY2024 | Sep 30, 2024 | $109.96M | +85.0% |
| Q2 FY2024 | Jun 30, 2024 | $117.61M | +106.3% |
| Q1 FY2024 | Mar 31, 2024 | $129.52M | +111.3% |
| Q4 FY2023 | Dec 31, 2023 | $57.42M | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | $59.45M | +14.7% |
| Q2 FY2023 | Jun 30, 2023 | $56.99M | +1.2% |
| Q1 FY2023 | Mar 31, 2023 | $61.29M | +8.4% |
| Q4 FY2022 | Dec 31, 2022 | $57.07M | -7.9% |
| Q3 FY2022 | Sep 30, 2022 | $51.85M | -20.6% |
| Q2 FY2022 | Jun 30, 2022 | $56.31M | -15.8% |
| Q1 FY2022 | Mar 31, 2022 | $56.53M | -8.7% |
| Q4 FY2021 | Dec 31, 2021 | $61.99M | -1.4% |
| Q3 FY2021 | Sep 30, 2021 | $65.29M | +29.5% |
| Q2 FY2021 | Jun 30, 2021 | $66.88M | +5.2% |
| Q1 FY2021 | Mar 31, 2021 | $61.92M | -4.0% |
| Q4 FY2020 | Dec 31, 2020 | $62.88M | -19.9% |
| Q3 FY2020 | Sep 30, 2020 | $50.42M | +3.3% |
| Q2 FY2020 | Jun 30, 2020 | $63.55M | +26.1% |
| Q1 FY2020 | Mar 31, 2020 | $64.49M | -5.1% |
| Q4 FY2019 | Dec 31, 2019 | $78.48M | -9.6% |
| Q3 FY2019 | Sep 30, 2019 | $48.82M | -45.8% |
| Q2 FY2019 | Jun 30, 2019 | $50.41M | +16.9% |
| Q1 FY2019 | Mar 31, 2019 | $67.98M | – |
| Q4 FY2018 | Dec 31, 2018 | $86.85M | – |
| Q3 FY2018 | Sep 30, 2018 | $90.01M | – |
| Q4 FY2017 | Dec 31, 2017 | $43.12M | – |
See a number that looks wrong?